BR112018074456A2 - anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos - Google Patents

anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos

Info

Publication number
BR112018074456A2
BR112018074456A2 BR112018074456-5A BR112018074456A BR112018074456A2 BR 112018074456 A2 BR112018074456 A2 BR 112018074456A2 BR 112018074456 A BR112018074456 A BR 112018074456A BR 112018074456 A2 BR112018074456 A2 BR 112018074456A2
Authority
BR
Brazil
Prior art keywords
antibodies
specifically bind
zika virus
relates
virus epitopes
Prior art date
Application number
BR112018074456-5A
Other languages
English (en)
Inventor
Corti Davide
Original Assignee
Humabs Biomed Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Humabs Biomed Sa filed Critical Humabs Biomed Sa
Publication of BR112018074456A2 publication Critical patent/BR112018074456A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

a invenção refere-se aos anticorpos, e fragmentos de ligação de antígeno dos mesmos, que potencialmente neutralizam a infecção de zikv. a invenção também se refere aos sítios antigênicos aos quais os anticorpos e fragmentos de ligação de antígeno se ligam, bem como aos ácidos nucleicos que codificam e células b imortalizadas que produzem tais anticorpos e fragmento de anticorpos. além disso, a invenção refere-se ao uso dos anticorpos e fragmentos de anticorpo da invenção em métodos de análise, bem como no diagnóstico, profilaxia e tratamento de infecção por zikv.
BR112018074456-5A 2016-07-13 2017-07-12 anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos BR112018074456A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2016/066684 WO2018010789A1 (en) 2016-07-13 2016-07-13 Novel antibodies specifically binding to zika virus epitopes and uses thereof
EPPCT/EP2016/066684 2016-07-13
PCT/EP2017/067581 WO2018011283A1 (en) 2016-07-13 2017-07-12 Novel antibodies specifically binding to zika virus epitopes and uses thereof

Publications (1)

Publication Number Publication Date
BR112018074456A2 true BR112018074456A2 (pt) 2019-03-19

Family

ID=56413654

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074456-5A BR112018074456A2 (pt) 2016-07-13 2017-07-12 anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos

Country Status (31)

Country Link
US (3) US11117954B2 (pt)
EP (2) EP3484915B1 (pt)
JP (2) JP7252888B2 (pt)
KR (1) KR102595764B1 (pt)
CN (2) CN116199775A (pt)
AU (1) AU2017297757A1 (pt)
BR (1) BR112018074456A2 (pt)
CA (1) CA3024374A1 (pt)
CL (2) CL2019000067A1 (pt)
CO (1) CO2019001111A2 (pt)
CR (1) CR20190066A (pt)
DK (1) DK3484915T3 (pt)
DO (2) DOP2019000006A (pt)
EA (1) EA201990243A1 (pt)
EC (1) ECSP19009170A (pt)
ES (1) ES2959883T3 (pt)
FI (1) FI3484915T3 (pt)
HR (1) HRP20231196T1 (pt)
HU (1) HUE063272T2 (pt)
IL (1) IL262710B1 (pt)
LT (1) LT3484915T (pt)
MX (1) MX2019000526A (pt)
MY (1) MY190553A (pt)
PE (1) PE20190398A1 (pt)
PH (1) PH12018502348A1 (pt)
PL (1) PL3484915T3 (pt)
SG (1) SG11201809879WA (pt)
SI (1) SI3484915T1 (pt)
UA (1) UA126381C2 (pt)
WO (2) WO2018010789A1 (pt)
ZA (1) ZA201807467B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6998935B2 (ja) 2016-07-13 2022-01-18 エボニック オペレーションズ ゲーエムベーハー 溶解された脂質含有バイオマスから脂質を分離する方法
MY191894A (en) 2016-10-13 2022-07-18 Nat Univ Singapore Antibodies that bind zika virus envelope protein and uses thereof
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
EP3527664A1 (en) 2018-02-15 2019-08-21 Evonik Degussa GmbH Method of isolating lipids from a lipids containing biomass
JP2019152666A (ja) * 2018-03-02 2019-09-12 富士レビオ株式会社 ジカウイルスを検出する方法及びキット
CA3098373A1 (en) 2018-04-24 2019-10-31 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Potent zika virus-specific and cross-neutralizing monoclonal antibodies to zika and dengue viruses following zikv infection or vaccination
US11976253B2 (en) 2018-05-15 2024-05-07 Evonik Operations Gmbh Method of isolating lipids from a lysed lipids containing biomass by emulsion inversion
CA3101855C (en) 2018-05-15 2023-06-20 Evonik Operations Gmbh Method of isolating lipids from a lipids containing biomass with aid of hydrophobic silica
WO2020061159A1 (en) * 2018-09-20 2020-03-26 Vanderbilt University Human antibodies to zika virus
WO2020078568A1 (en) 2018-10-19 2020-04-23 Humabs Biomed Sa Antibodies and methods for treatment of lyssavirus infection
WO2020092564A1 (en) * 2018-10-31 2020-05-07 Icahn School Of Medicine At Mount Sinai Human antibodies targeting zika virus ns1, ns1 polypeptides and uses thereof
US20220332800A1 (en) 2018-11-20 2022-10-20 Takeda Vaccines, Inc. Novel anti-zika virus antibodies and uses thereof
WO2020245663A1 (en) * 2019-06-01 2020-12-10 Institut Pasteur Nanobody-based ns1 assay for the specific diagnosis of acute zika virus infection
WO2021101739A1 (en) * 2019-11-19 2021-05-27 Vanderbilt University Human antibodies that neutralize zika virus and methods of use therefor
CN111100201B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 针对寨卡病毒囊膜蛋白的鼠源单克隆抗体
CN111138534B (zh) * 2019-12-31 2021-09-28 武汉班科生物技术股份有限公司 寨卡病毒囊膜蛋白的鼠源单克隆抗体
JP7471555B2 (ja) * 2020-02-20 2024-04-22 国立感染症研究所長 フラビウイルス交差中和抗体及び医薬組成物
EP4153222A1 (en) 2020-05-20 2023-03-29 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2021236223A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for determining the potency of antigens
WO2021236225A1 (en) 2020-05-20 2021-11-25 Takeda Vaccines, Inc. Method for detection of zika virus specific antibodies
WO2022001803A1 (zh) * 2020-06-28 2022-01-06 神州细胞工程有限公司 一种降低病毒ade效应的方法
EP4313102A2 (en) * 2021-04-01 2024-02-07 A2 Biotherapeutics, Inc. Polypeptides targeting hla-a*11 and methods of use thereof
CN112921124B (zh) * 2021-04-08 2021-09-28 广东创晟控股集团有限公司 一种快速检测病毒的试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
US7785799B2 (en) 2002-08-16 2010-08-31 The Board Of Regents Of The University Of Texas System Compositions and methods related to flavivirus envelope protein domain III antigens
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
EP1641827A2 (en) 2003-06-27 2006-04-05 Biogen Idec MA Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
NZ581395A (en) 2007-05-14 2012-08-31 Biogen Idec Inc Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
WO2010046775A2 (en) 2008-10-22 2010-04-29 Institute For Research In Biomedicine Methods for producing antibodies from plasma cells
BR112015021341B1 (pt) * 2013-03-15 2023-03-28 Dana-Farber Cancer Institute Inc. Anticorpos monoclonais humanizados isolados neutralizantes de flavivírus e usos terapêuticos dos mesmos
US20190194260A1 (en) 2016-03-11 2019-06-27 The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Live attenuated zika virus vaccine
WO2017181098A2 (en) * 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
TW201815821A (zh) 2016-07-18 2018-05-01 美商再生元醫藥公司 抗茲卡病毒抗體及使用方法
JP7216705B2 (ja) 2017-07-28 2023-02-02 ニンバス ラクシュミ， インコーポレイテッド Ｔｙｋ２阻害剤およびその使用方法

Also Published As

Publication number Publication date
JP2019533425A (ja) 2019-11-21
JP2023062036A (ja) 2023-05-02
IL262710A (en) 2018-12-31
US11912757B2 (en) 2024-02-27
CN109563157B (zh) 2023-01-17
IL262710B1 (en) 2024-01-01
EP3484915A1 (en) 2019-05-22
PL3484915T3 (pl) 2024-03-25
PE20190398A1 (es) 2019-03-13
CL2019000067A1 (es) 2019-07-26
HRP20231196T1 (hr) 2024-01-19
CN116199775A (zh) 2023-06-02
KR20190027382A (ko) 2019-03-14
MX2019000526A (es) 2019-05-02
EP3484915B1 (en) 2023-08-16
ECSP19009170A (es) 2019-02-28
DOP2021000026A (es) 2021-07-30
LT3484915T (lt) 2023-10-10
DOP2019000006A (es) 2019-03-31
FI3484915T3 (fi) 2023-11-15
AU2017297757A1 (en) 2018-11-22
EA201990243A1 (ru) 2019-07-31
US11117954B2 (en) 2021-09-14
EP4342911A1 (en) 2024-03-27
CA3024374A1 (en) 2018-01-18
CO2019001111A2 (es) 2019-08-20
ZA201807467B (en) 2024-04-24
PH12018502348A1 (en) 2019-03-25
US20210363227A1 (en) 2021-11-25
US20210355198A1 (en) 2021-11-18
MY190553A (en) 2022-04-27
CL2021002994A1 (es) 2022-09-09
WO2018010789A1 (en) 2018-01-18
US20190256582A1 (en) 2019-08-22
CR20190066A (es) 2019-09-10
DK3484915T3 (da) 2023-10-09
UA126381C2 (uk) 2022-09-28
ES2959883T3 (es) 2024-02-28
WO2018011283A1 (en) 2018-01-18
CN109563157A (zh) 2019-04-02
JP7252888B2 (ja) 2023-04-05
SG11201809879WA (en) 2018-12-28
KR102595764B1 (ko) 2023-10-30
SI3484915T1 (sl) 2024-02-29
HUE063272T2 (hu) 2024-01-28

Similar Documents

Publication Publication Date Title
BR112018074456A2 (pt) anticorpos que se ligam especificamente aos epítopos do zika vírus e usos dos mesmos
BR112018012352A2 (pt) anticorpos anti-lag3 e fragmentos de ligação ao antígeno
BR112018071276A2 (pt) anticorpos anti-il-33, composições, métodos e usos dos mesmos
BR112018002406A2 (pt) anticorpos que neutralizam potentemente o vírus da hepatite b e usos dos mesmos
BR112017010298A2 (pt) anticorpos que neutralizam de modo potente vírus da raiva e outros lissavírus e usos dos mesmos
BR112017003108A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos para produção de um anticorpo ou fragmento de ligação a antígeno, para tratamento de câncer e de uma infecção ou doença infecciosa, para detecção da presença de um peptídeo de tigit ou um fragmento do mesmo e para aumentar a atividade de uma célula imune e a atividade antitumoral de um anticorpo anti-tigit, vacina, e, uso de um anticorpo ou fragmento de ligação a antígeno
BR112018012344A2 (pt) anticorpos que se ligam especificamente a hla-dr e seus usos
BR112017006203A2 (pt) anticorpos isolado, caninizado e monoclonal ou fragmento de ligação ao antígeno dos mesmos, ácido nucleico isolado, vetor de expressão, célula hospedeira, peptídeo antigênico isolado, proteína de fusão, composição farmacêutica, e, método de aumento da atividade de uma célula imune.
PH12017500890A1 (en) Antibody drug conjugates
BR112018003326A2 (pt) anticorpos de ligação de linfopoietina estromal tímica (tslp) e métodos de uso dos anticorpos
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
BR112018006360A2 (pt) anticorpos agonísticos que se ligam especificamente ao cd40 humano e métodos de uso
BR112016011401A2 (pt) moduladores de aplnr e utilizações dos mesmos
PH12020550025A1 (en) Multispecific antibodies specifically binding to zika virus epitopes and uses thereof
BR112018070948A2 (pt) anticorpos anti-psma e utilização dos mesmos
BR112016004324A2 (pt) anticorpos
BR112022002837A2 (pt) Anticorpo anti-vd1 ou fragmento do mesmo, anticorpo multiespecífico isolado ou fragmento do mesmo, anticorpo humano e anticorpo multiespecífico isolado humano ou fragmento do mesmo
BR112016018082A2 (pt) ?anticorpos úteis na imunização passiva de influenza e composições, combinações e métodos para uso dos mesmos?
BR112014023063A2 (pt) anticorpos que neutralizam rsv, mpv e pvm e usos dos mesmos
WO2016075546A3 (en) Antibodies that neutralize ebola virus and uses thereof
EA201992186A1 (ru) Антитела к par2 и пути их применения

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: HUMABS BIOMED SA (CH)

B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]